Overview

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Status:
Completed
Trial end date:
2017-06-07
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of pazopanib and vorinostat that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Vorinostat